3 Results for "

D0316

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "D0316" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-137433
CAS No.: 1835667-63-4
Purity:  99.86%
Synonyms: D-0316
Research Areas:  

Cancer

Befotertinib (D-0316) is an orally active EGFR inhibitor and ABCB1 inhibitor. Befotertinib selectively targets EGFR mutations including EGFR T790M, EGFR L858R and delE746-A750, forms covalent bonds with EGFR C797, inhibits oncogenic signaling pathways, and exerts antiproliferative effects. Befotertinib inhibits ABCB1-mediated drug efflux, activates the ATPase activity of ABCB1, acts as a chemosensitizer and apoptosis enhancer, and restores the sensitivity of multidrug-resistant cancer cells. Befotertinib can be used in research related to multidrug-resistant cancers and non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-D0316
CAS No.: 1533-78-4
Synonyms: DR 167:1
Research Areas:  

Others

Disperse red 167:1 (DR 167:1) is an azo disperse dye . Disperse red 167:1 interacts with the active site of nitroreductase, leading to the reduction of its nitro group to amine metabolites. Disperse red 167:1 is mainly used for dyeing hydrophobic fibers such as polyester, and is also applicable to dyeing research on plastics, textiles and other materials .
loading...
    loading...
Cat. No.: HY-137433A
CAS No.: 2226167-02-6
Synonyms: D-0316 mesylate
Research Areas:  

Inflammation/Immunology Cancer

Befotertinib (D-0316) mesylate is an orally active EGFR inhibitor and ABCB1 inhibitor. Befotertinib mesylate selectively targets EGFR mutations including EGFR T790M, EGFR L858R and delE746-A750, forms covalent bonds with EGFR C797, inhibits oncogenic signaling pathways, and exerts antiproliferative effects. Befotertinib mesylate inhibits ABCB1-mediated drug efflux, activates the ATPase activity of ABCB1, acts as a chemosensitizer and apoptosis enhancer, and restores the sensitivity of multidrug-resistant cancer cells. Befotertinib mesylate can be used in research related to multidrug-resistant cancers and non-small cell lung cancer .
loading...
    loading...